were reactive.
Preoperative radiotherapy in a total skin dose of 10,000 rad produced a transient tumour specific reaction 24 h after therapy in a single case. Following local tumour excision in patients given preoperative irradiation, 2 cases which had previously demonstrated tumour specific CMI lost reactivity. Among 14 tumour-free individuals tested only after preoperative radiotherapy and surgery, at intervals from 5 days to 13 years, a single case gave tumour specific CMI.
Palliative irradiation in doses 4000-4960 rad to the inguinal or axillary lymph nodes was found to induce a generalized lymphopenia within 48 h after treatment. Lymphoid cell preparations from patients with localized melanoma contained significantly increased numbers of immature cells (lymphoblasts and myeloblasts) and myeloid precursor elements. Those prepared from patients with disseminated disease had in addition elevated levels of eosinophils but reduced numbers of recoverable lymphocytes.
IMMUNITY to malignant melanoma has been the subject of numerous in vitro studies. Specific antigen(s) unique to melanoma cells have been detected using assays for both cellular and humoral immunity (Currie, Lejeune and Fairley, 1971; Currie, 1973; Cochran et al., 1973; de Vries, Riimke and Bernheim, 1972; Fossati et al., 1971; Hellstrom et al., 1971 Hellstrom et al., , 1973a Heppner et al., 1973; Jehn, Nathanson and Schwartz, 1970; Morton et al., 1968 Morton et al., , 1971 Lewis et al. , 1969) . Qualitatively, these assays have usually demonstrated common antigen(s) in melanoma target cells derived from different donors. Discordant results between melanoma cells from different donors have also been reported, which could indicate the presence of unique antigen(s) in a given tumour (de Vries et al., 1972; Fossati et al., 1971; Lewis et al., 1969) .
Quantitatively, the humoral response to melanoma has been shown to correlate + Present address: Department Microbiology and Immunology, UCLA School of Medicine, Los Angeles California 90024, USA. 22 with extent of disease (Morton et al., 1968; Lewis et al., 1969) . A diminution in detectable cellular immunity has also been reported in some melanomapatients with advancing disease (Cochran et al., 1973; de Vries et al., 1972; Hellstrom et al., 1973a, b; Heppner et al., 1973) .
The present article represents an attempt to quantitate the cellular response to tumour in patients with skin or ocular melanoma, to determine its incidence in different stages of disease, and in patients clinically tumour-free after local surgery or preoperative radiotherapy.
MATERIALS AND METHODS
Melanoma patients.-33 cases of clinically verified or suspected malignant melanoma were studied. The site of origin of the tumour and sex distribution of these patients are presented in Table I Appendix. The clinical details of the patients with malignant melanoma or melanosis of the eye are given in Table II Appendix. Malignant melanoma of the skin was staged according to extent of tumour spread, as shown in Table III of the Appendix. Details of surgery and radiotherapy techniques used in treatment of melanoma and transitional cell carcinoma of the urinary bladder are given in the Appendix.
Clinical controls. -Table IV Appendix summarizes 42 patients with unrelated neoplasms tested in parallel with the melanoma patients in this series. In addition, 10 normal healthy controls were included. Clinical details of these patients are presented in the Appendix.
Cell mediated immunity.-CMI was assayed as described previously for patients with carcinoma of the urinary bladder (O'Toole, 1973; O'Toole et al., 1972a O'Toole et al., , b, 1973a O'Toole et al., , b, 1974 . Twenty-four separate experiments were carried out; all blood samples were received coded and the code was not broken until the residual target cell numbers had been calculated.
Effector cells.-These were prepared rou tinely as follows: 20-50 ml of defibrinated blood were obtained from each donor. The bulk of the erythrocytes were sedimented over 3% gelatin w/v in Tris buffered Hanks' solution (Coulson and Chalmers, 1964) , for 1 h at 37°C. The leucocyte plasma supernatant was transferred to a nylon wool column and incubated for 30 min at 37°C, to remove adherent cells (Greenwalt, Galewski and McKenna, 1962) . The cells were eluted from the column and washed 3 times with Tris buffered Hanks' solution containing 2.5% heat inactivated foetal calf serum (TH). The remaining erythrocytes were lysed by exposure to 0.83% Tris-ammonium chloride solution at 4°C for 5-10 min (Boyle, 1968) . The cells were then spun down and washed a further 3 times in TH. Cytocentrifuge (Dore and Balfour, 1965) preparations made from each donor's " purified " effector cells were stained with May-Grinwald Giemsa. Differential counts were made based on a minimum of 500 cells/preparation (Table V) . Target cells.-Primary cultures were established from explants of metastatic skin melanomata. MEL-I from a draining lymph node of patient S.M. in passages 1-24 provided target cells in 22 experiments. These cells were epithelioid in appearance and produced tumours in nude mice (E. Kristensen and J. Kieler, personal communication). A melanoma cell line RPMI 7931 derived from metastatic cutaneous melanoma (established by R. Gerner and G. Moore) was used in 13 experiments. The following nonmelanoma target cells were used: the cell strain J82 derived from TCC in passages 2-32; the established cell lines from TCC, T24 (Bubenik et al., 1973) , RT4 (Rigby and Franks, 1970) and from non-malignant bladder HCV-29 (established by J. Fogh). The pattern of tumour specific reactions by lymphoid cells from patients with TCC on these lines has been described in detail previously (O'Toole, 1973; O'Toole et al., 1972a O'Toole et al., , b, 1973a O'Toole et al., , b, 1974 . All cultures were maintained in tissue culture medium 199, with Hanks' salts containing 10% heat inactivated calf serum, with 100 i.u. penicillin, 100 ,ig foetal streptomycin and 0 3 mg glutamine/ml. The tissue culture passage number (TC) is presented for the primary cell cultures for each experiment reported in the results section.
Microcytotoxicity assay.-This was based on that described by Takasugi and Klein (1970) from donors with TCC only on TCC targets with no effect on melanoma targets (Tables III, IV, V) .
Clinical observations in relation to CMI Ocular tumour.-The reactions obtained with effector cells from this group of patients are depicted in Table VII . Of the 5 patients tested before surgery, 2 showed melanoma specific reactions on targets derived from skin melanoma. Quantitative data on patient L.B. are given in Table VI . Significant effects were produced on both allogeneic melanoma targets, MEL-1 and RPMI 7931, with no effect on J82, a histogenically unrelated allogeneic target. In the same experiment, effectors from patient J.L.
(stage I skin melanoma) showed the same range of specificity as LB's cells while effectors from S.O., a patient with metastatic skin melanoma, produced nonspecific effects.
Effect of surgery on CMI in patients with ocular tumours.-Only 2 patients were tested after surgery, at a 3-4 month interval; both failed to respond (Table  VII) . Patient F.E. had also been tested before operation and showed a nonspecific effect at that time. The only detectable difference in F.E.'s effector cell preparations was that 1% immature cells which were present before surgery were absent at test 4 months after treatment.
Malignant melanoma of the skin.
Among 3 patients tested before therapy ( Table V Appendix. A drastic lymphopenia was apparent within 48 h of cessation of therapy. Similarly, effects have been observed after local radiotherapy in patients with TCC to the region of the urinary bladder, the duration of which also depended on the clinical situation (whether tumour-free or not) of the patient post therapy. (B. Unsgaard, to be published.) It should be noted that these patients were treated palliatively and all succumbed to widespread metastases (Tables II, VIII, X) . DISCUSSION These results demonstrate that the incidence and type of cytotoxicity produced by effector cell preparations from melanoma patients are influenced by tumour burden and therapeutic intervention. The method of effector cell preparation was shown to yield a heterogeneous population of lymphoid and myeloid precursor cells from certain patient groups, particularly those with metastatic tumour. Detailed analyses of the composition of effector cell preparations used in in vitro assays for CMI from patients in different clinical situations have not previously been reported. The high incidence of nonspecific effects on histogenically diverse targets observed with preparations from patients with metastases could implicate non-lymphocytic cells in these effects. Neutrophils, eosinophils and myeloid precursor cells are known to be rich in hydrolytic enzymes. Such enzymes have been shown to exert a powerful cytolytic effect on a variety of mammalian target cells in vitro (Edelson and Cohn, 1973) . However, effector cell preparations from patients with basal cell carcinoma also showed a significant incidence of nonspecific effects despite no obvious nonlymphocytic contamination. Elucidation of the role and target specificity range of different effector cell populations in in vitro cytotoxicity assays will require the procurement of more homogeneous populations of effector cell types and standardization of preparative procedures.
Tumour specific cytotoxicity could be quantitated in certain patients with ocular and skin melanomata. A longterm cell line and a primary culture derived from metastatic skin melanomata were compared as allogeneic targets and found to give qualitatively comparable results. It has previously been reported that sera from some patients with ocular melanoma contain antibodies which react specifically with skin melanoma target cells (Nairn et al., 1972; Federman, Lewis and Clark, 1974) . Our data demonstrate cross reactivity also at the cellular level.
The incidence of tumour specific CMI detected in this series of melanoma patients contrasts sharply with that reported for patients with the same diagnosis and in similar clinical situations by Hellstrom et al. (1971, 1973a, b) . These authors found that the majority of clinically cured patients had tumour specific CMI during a 1-2 year observation period post surgery. In a similar group of patients we have found tumour specific C1II a rare phenomenon. Fossati et al. (1971) reported a high incidence of tumour specific CMI in patients 1-6 months after surgery; in the present series we observed reactivity mainly during a 3-4 week interval after surgery. Similar results have been reported by Nairn et al. (1972) who found no reactivity in melanoma patients tested 2 months post surgery.
Using similar in vitro assays, several authors have reported a diminution of tumour specific CMI in some melanoma patients with disseminated disease (De Vries et al., 1972; Hellstr6m et al., 1973a, b; Heppner et al., 1973) . Currie et al. (1971) reported a correlation in the incidence of CMI and extent of disease; however, this was not apparent after more extensive washing of effector cell preparations (Currie, 1973) . Cochran et al. (1973) using a leucocyte migration inhibition assay, found correlations with the stage of disease. In the present series, tumour specific reactions were detected only in patients with localized disease while patients with disseminated melanoma were either nonreactive or showed nonspecific cytotoxicity.
It should be noted that all effector cell preparations tested were washed a minimum of 6 times during preparation. The incidence of tumour specific CMI in patients with TCC of the bladder has been shown to correlate with extent of disease, patients with localized tumours showing the highest incidence (O'Toole et al., 1972a (O'Toole et al., , b, 1973a .
Comparisons of the clinical significance of the incidence of CMI in patients with melanoma, reported by different authors, cannot at present be made due to the disparity in methods of effector cell preparation, effector: target cell ratio and probable heterogeneity.
Significant clinical correlations have, however, been reported between the level of specific serum blocking factor (SBF) for CMI, in vitro and extent of disease (Hellstrom et al., 1973b) . In vitro quantitation of tumour specific CMI and its relation to the serum levels of SBF remain to be determined. However, a correlation between the level of tumour specific antibodies and the extent of disease has been documented in patients with malignant melanoma (Morton et al., 1968 (Morton et al., , 1971 Lewis et al., 1969) .
Local radiotherapy and surgery have been shown to modify tumour specific CMI in patients with TCC of the bladder (O'Toole et al., 1972a (O'Toole et al., , b, 1973a . The maintenance of CMI in these patients was shown to be dependent on the presence of critical amounts of tumour material in the body. Successful removal of tumour by surgery led to the disappearance of specific CMI within 2-3 weeks post surgery. The majority of tumour-free melanoma patients tested at intervals greater than 1 month post surgery in this series also lacked tumour specific CMI. Radiotherapy in patients with TCC could induce a specific CMI in some cases which were previously nonreactive. This was observed also in a single melanoma case in the present series.
Patients with TCC given preoperative radiotherapy were shown to maintain tumour specific CMI for a period of several months after surgery (O'Toole et al., 1972b (O'Toole et al., , 1973a . This effect was not observed in the melanoma patients given preoperative radiotherapy. Irradiation technique, duration, time interval between radiotherapy and surgery and the actual tumour volume irradiated could determine these differences.
Tumour specific CMI has not been observed in patients with TCC who have remained tumour-free during a 1-12 year period after radiotherapy. However, responses were detected in patients who developed local recurrences after therapy (O'Toole et al., 1973a) . The relevance of tumour specific CMI to the aetiology of disease in the 2 melanoma patients who showed tumour specific reactionis 2 and 12-13 years after therapy respectively, remains to be elucidated.
Patients with metastatic melanoma given palliative local radiotherapy to the axillary or inguinal region in doses of 4000-4960 rad were seen to develop pronounced lymphopenia when tested 2-14 days after treatment. Similar effects have been observed after local radiotherapy (Thomas et al., 1971; Stjernsward et al., 1973; Chee, Ilberry and Rickinson, 1974) Surgery.-The primary tumour was excised in patients with stage I skin melanoma. Stage II patients were treated by local excision of the primary and dissection of the draining lymph nodes. For stage III the primary tumour was excised to reduce tumour burden, and then cytostatics and/or external radiation were given palliatively.
Radiotherapy.-Stage I malignant melanoma of the skin is treated at this hospital by preoperative radiotherapy. This was given with a Dermopan 2 unit operated at 10-50 kV, 25 mA, either without filter or with 0 3-1 mm Al. The total skin dose was 10,000 rad, given with a margin, followed 24-120 h later by excision of the treated area with about 1 cm margin.
Therapy and clinical details of patients with transitional cell carcinoma of the urinary bladder:
Patients receiving radiotherapy were given either 60Co teletherapy or betatron 18 MeV roentgen. Two patients received 4000-4200 rad preoperatively and 12 had full dose treatment of 6270-6725 rad. Patients treated surgically had transurethral resection only or total cystectomy 1 month after radiotherapy. The clinical staging of APPENDIX (Table IV) is that proposed by UICC (1963) ; and the histological grading used was according to Bergkvist et al. (1965 
